How to Monitor Community ECT Response in Severe Depression
How should clinicians track depression, anxiety, and cognition during an acute community ECT course for severe treatment-resistant depression?
Patients referred for ECT in community practice often have severe, highly treatment-resistant depression and may not achieve the remission rates commonly cited from clinical trials. This guide summarizes the symptom-monitoring process actually used in the study so clinicians can follow response, remission, and associated anxiety change during an acute ECT series.
-
Define the acute ECT course you are tracking
In this clinic, the acute series involved ECT 3 times per week, typically on a Monday, Wednesday, and Friday schedule. A complete acute series was defined as 12 treatments, and study data were collected for the first 12 treatments received during the acute series.
-
Collect baseline symptom and cognitive measures before treatment starts
Before the first ECT treatment, obtain a PHQ-9, GAD-7, HAMD-17, and MoCA. In the study, PHQ-9 and GAD-7 were completed prior to each ECT treatment, while HAMD-17 and MoCA were administered before the first, sixth, and last ECT treatments.
-
Repeat depression and anxiety ratings before each treatment
Have patients complete the PHQ-9 and GAD-7 prior to every ECT session. This allows clinicians to follow symptom trajectory across the acute course and calculate change scores by subtracting final scores from initial scores at the conclusion of treatment.
-
Reassess depression severity and cognition at mid-course and end-point
Administer the HAMD-17 and MoCA again before the sixth and last ECT treatments. This mirrors the study's schedule for checking depressive symptom change and monitoring cognition during the course.
-
Classify depression response and remission using the study thresholds
Define depression response on the PHQ-9 as a 50% or greater reduction from baseline. Define PHQ-9 remission as a final score less than 5. If using the study's secondary measures, define HAMD-17 response as a 50% or greater reduction and HAMD-17 remission as a score of 7 or lower.
-
Classify anxiety response alongside depression change
Define anxiety response as a 50% or greater reduction in GAD-7 score. In this sample, anxiety improvement tracked with depression improvement, and 84.2% of patients who responded on the PHQ-9 also responded on the GAD-7.
-
Use community-based expectations when counseling patients
In this community clinic sample, 54.3% of patients achieved PHQ-9 response and 31.4% achieved PHQ-9 remission. These rates are useful for setting expectations in highly treatment-resistant community populations, where outcomes may be lower than the 70% to 90% remission rates often cited from controlled trials.
Clinical Considerations
- This was a small retrospective chart review, so the workflow reflects how one community clinic monitored patients rather than a validated universal protocol.
- Only 13 of 35 patients completed 12 treatments, and reasons for early discontinuation were missing.
- ECT delivery was not standardized across psychiatrists, including treatment titration and selection of bilateral versus right unilateral electrode placement.
- The sample excluded patients with baseline PHQ-9 scores below 20 and those with bipolar disorder, schizophrenia, schizoaffective disorder, or dementia.
Bottom Line
During an acute community ECT series, track PHQ-9 and GAD-7 before every treatment and HAMD-17 and MoCA at baseline, mid-course, and the last treatment, then interpret outcomes using response as at least 50% symptom reduction and PHQ-9 remission as less than 5.
